| Literature DB >> 34677441 |
Wei-Mao Zhong1,2,3, Xiao-Yi Wei4, Yu-Chan Chen5, Qi Zeng1,3, Jun-Feng Wang1, Xue-Feng Shi1, Xin-Peng Tian1, Wei-Min Zhang5, Fa-Zuo Wang1, Si Zhang1.
Abstract
To enlarge the chemical diversity of Eurotium sp. SCSIO F452, a talented marine-derived fungus, we further investigated its chemical constituents from a large-scale fermentation with modified culture. Four pairs of new salicylaldehyde derivative enantiomers, euroticins F-I (1-4), as well as a known one eurotirumin (5) were isolated and characterized. Compound 1 features an unprecedented constructed 6/6/6/5 tetracyclic structures, while 2 and 3 represent two new types of 6/6/5 scaffolds. Their structures were established by comprehensive spectroscopic analyses, X-ray diffraction, 13C NMR, and electronic circular dichroism calculations. Selected compounds showed significant inhibitory activity against α-glucosidase and moderate cytotoxic activities against SF-268, MCF-7, HepG2, and A549 cell lines.Entities:
Keywords: Eurotium sp.; bioactivities; marine-derived fungi; natural products; salicylaldehyde derivative enantiomers
Mesh:
Substances:
Year: 2021 PMID: 34677441 PMCID: PMC8538301 DOI: 10.3390/md19100543
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–5.
1H and 13C NMR Data for 1 in DMSO-d6 and 2 in acetone-d6 (700, 175, TMS, δ in ppm, J in Hz).
| 1 | 2 | |||
|---|---|---|---|---|
| No. |
|
| ||
| 1 | 120.6 | 121.1 | ||
| 2 | 143.0 | 144.6 | ||
| 3 | 120.1 | 127.7 | ||
| 4 | 110.3 | 6.36, s | 117.0 | 6.51, s |
| 5 | 145.7 | 148.2 | ||
| 6 | 125.6 | 122.4 | ||
| 7 | 35.8 | 2.66, d (17.3) | 95.9 | 5.58, s |
| 2.49, overlap | ||||
| 8 | 106.2 | |||
| 9 | 25.8 | 1.53, s | ||
| 1′ | 122.6 | 6.27, d (9.7) | 29.2 | 3.27, m |
| 2′ | 131.6 | 5.67, d (9.7) | 123.8 | 5.28, br t (7.4) |
| 3′ | 75.7 | 132.6 | ||
| 4′ | 28.0 | 1.31, s | 25.9 | 1.72, s |
| 5′ | 27.8 | 1.29, s | 17.8 | 1.69, s |
| 1″ | 74.1 | 5.09, s | 41.3 | 2.30, dd (12.0, 8.1) |
| 2″ | 84.8 | 3.75, t (6.7) | 67.9 | 4.61, ddd (8.1, 7.7, 5.0) |
| 3″ | 35.1 | 1.45, m | 35.0 | 2.49, m |
| 1.71, overlap | ||||
| 4″ | 25.2 | 1.32, overlap | 29.5 | 1.92 m |
| 1.39, m | ||||
| 5″ | 31.5 | 1.27, overlap | 49.8 | 1.33, m |
| 6″ | 22.5 | 1.28, overlap | 80.8 | 4.31, dq (10.4, 6.2) |
| 7″ | 14.4 | 0.86, t (6.7) | 21.8 | 1.30, d (6.2) |
| 5-OH | 8.99, s | |||
| 7-OMe | 55.4 | 3.45, s | ||
a Recorded at 175 MHz. b Recorded at 700 MHz.
Figure 2Key 1H-1H COSY, HMBC, and ROESY correlations of compounds 1 and 2.
Figure 3Linear regression analysis of calculated 13C NMR shifts of (8R,1″S,2″S)-1 (left) and (8R,1″S,2″R)-1 (right) against the measured shifts of 1 and the DP4+ probability for assignment of 1 to the candidate stereoisomers.
Figure 4Comparison between M06/TZVP/PCM calculated and experimental ECD spectra of 1 in MeOH.
Figure 5Comparison between PBE0/TZVP/PCM calculated and experimental ECD spectra of 2 and 4 in MeOH.
1H and 13C NMR data for 3 in acetone-d6 and 4 in DMSO-d6 (700, 175, TMS, δ in ppm, J in Hz).
| 3 | 4 | |||
|---|---|---|---|---|
| No. |
|
| ||
| 1 | 128.3 | 41.1 | 2.80, d (17.8) | |
| 2.51, overlap | ||||
| 2 | 140.1 | 169.4 | ||
| 3 | 130.8 | 126.7 | 6.01, s | |
| 4 | 112.9 | 6.60, s | 209.5 | |
| 5 | 158.1 | 76.4 | ||
| 6 | 112.9 | |||
| 7 | 57.3 | 4.99, d (16.3) | ||
| 4.81, d (16.3) | ||||
| 1′ | 122.4 | 6.46, d (9.9) | 121.7 | 6.68, d (15.8) |
| 2′ | 138.0 | 6.07, d (9.9) | 149.5 | 6.49, d (15.8) |
| 3′ | 77.1 | 69.5 | ||
| 4′ | 28.0 | 1.43, s | 29.5 | 1.24, s |
| 5′ | 27.7 | 1.42, s | 29.5 | 1.24, s |
| 1″ | 197.5 | 37.4 | 1.50, dt (12.6, 3.9) | |
| 1.39, dt (12.6, 4.8) | ||||
| 2″ | 92.3 | 23.2 | 1.25 overlap | |
| 1.10 m | ||||
| 3″ | 37.0 | 2.11, m | 29.5 | 1.21, overlap |
| 1.83, m | ||||
| 4″ | 23.6 | 1.53, m | 28.7 | 1.22, overlap |
| 1.35, overlap | ||||
| 5″ | 32.8 | 1.30, overlap | 31.2 | 1.20, overlap |
| 6″ | 23.2 | 1.29, overlap | 22.1 | 1.24, overlap |
| 7″ | 14.3 | 0.88, t (7.0) | 14.0 | 0.84, t (7.2) |
| 5-OH | 11.2, s | |||
| 2″-OH | 5.90, br s | |||
a Recorded at 125 MHz. b Recorded at 500 MHz. c Recorded at 175 MHz. d Recorded at 700 MHz.
Figure 6Key 1H-1H COSY and HMBC correlations of compounds 3 and 4.
Figure 7X-ray ORTEP drawing of compound (−)-5.
Scheme 1Proposed biosynthetic pathway of compounds 1–5.
Cytotoxic activities of compounds (+)-1, (−)-1, (+)-2, (−)-2, (±)-3, (+)-4, (−)-4, (+)-5, and (−)-5 against tumor cells a.
| Compounds | IC50 (μM) | |||
|---|---|---|---|---|
| SF-268 | MCF-7 | HepG2 | A549 | |
| (+)- | 21.88 ± 0.96 | 27.17 ± 2.03 | 28.00 ± 1.68 | 33.78 ± 0.34 |
| (−)- | 37.31 ± 2.46 | 28.00 ± 1.57 | 30.72 ± 3.55 | 33.43 ± 1.50 |
| (+)- | >100 | >100 | >100 | >100 |
| (−)- | >100 | >100 | >100 | >100 |
| (±)- | >100 | >100 | >100 | >100 |
| (+)- | 12.74 ± 0.46 | 20.51 ± 1.54 | 19.88 ± 5.09 | 16.90 ± 0.92 |
| (−)- | 23.73 ± 3.88 | 23.56 ± 2.99 | 19.53 ± 2.70 | 22.15 ± 1.54 |
| (+)- | 21.98 ± 0.88 | 55.59 ± 4.85 | 41.18 ± 2.63 | 47.34 ± 0.71 |
| (−)- | 35.65 ± 1.79 | 50.67 ± 2.48 | 40.69 ± 2.76 | 42.61 ± 1.43 |
| Adriamycin | 1.19 ± 0.03 | 2.02 ± 0.04 | 1.99 ± 0.07 | 1.73 ± 0.04 |
a The results were mean ± SD (SD = standard deviation). Positive control: Adriamycin.
Antioxidative and α-glucosidase inhibitory activities of compounds (+)-1, (−)-1, (+)-2, (−)-2, (±)-3, (+)-4, (−)-4, (+)-5, and (−)-5.
| Compounds | Antioxidative Activity EC50 (μM) | |
|---|---|---|
| (+)- | 42.34 ± 3.85 | >100 |
| (−)- | 41.40 ± 2.68 | >100 |
| (+)- | 76.90 ± 0.99 | 38.04 ± 2.73 |
| (−)- | 77.07 ± 1.88 | 79.71 ± 1.74 |
| (±)- | >100 | 16.31 ± 1.68 |
| (+)- | >100 | >100 |
| (−)- | >100 | >100 |
| (+)- | >100 | 89.41 ± 7.86 |
| (−)- | >100 | >100 |
| Ascorbic acid a | 11.35 ± 0.56 | |
| Acarbose b | 32.92 ± 1.03 |
a Positive control for antioxidative activity; b Positive control for α-glucosidase inhibitory activity.